All type of patients: 29 trials - Al Sifri - Arechavaleta - Barzilai - Pérez-Monteverde - Reasner - Stafford - Aschner - Derosa - Iwamoto - Rigby - Vilsbøll - Mohan - Chan - Nonaka - raz - Goldstein - Goldstein (sit vs met) - Goldstein (sit+met vs met) - Hanefeld - Hermansen - Nauck - Scott* (sit vs glipi) - Scott* (sit vs pbo) - Scott** (sit vs pbo on top met) - Aschner - Charbonnel - Raz - Rosenstock - Rosenstock (sit on top pio vs pbo)
All types of patients: 29 trials - Al Sifri - Arechavaleta - Barzilai - Pérez-Monteverde - Reasner - Stafford - Aschner - Derosa - Iwamoto - Rigby - Vilsbøll - Mohan - Chan - Nonaka - raz - Goldstein - Goldstein (sit vs met) - Goldstein (sit+met vs met) - Hanefeld - Hermansen - Nauck - Scott* (sit vs glipi) - Scott* (sit vs pbo) - Scott** (sit vs pbo on top met) - Aschner - Charbonnel - Raz - Rosenstock - Rosenstock (sit on top pio vs pbo)
Patients inadequately controlled on metformin: 3 trials - Nauck - Scott** (sit vs pbo on top met) - Charbonnel
Patients inadequately controlled on monotherapy : 4 trials - Nauck - Scott** (sit vs pbo on top met) - Charbonnel - Rosenstock (sit on top pio vs pbo)
Patients with insufficient glycaemic control with bitherapy: 1 trials - Hermansen
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
